Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY: PFE )

25.53 -0.11 (-0.43%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
3 Beautiful Blue-Chip Stocks You Can Buy for Less Than $100
Wise investors consider three blue-chip stocks under $100, no matter what happens during the rest of the year. 
Via InvestorPlace
2 Beaten-Down Dividend Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
High yields that could continue growing for the foreseeable future make these stocks no-brainer buys right now. 
Via The Motley Fool
2 Stocks Down More Than 30% to Buy Right Now
These stocks have suffered as the demand for their biggest product -- the coronavirus vaccine -- waned. 
Via The Motley Fool
Exposures COVID-19
Pfizer Declares Third-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
What's Going On With Pfizer Shares Wednesday?
Pfizer Inc. (NYSE: PFE) is experiencing notable stock movement on Wednesday afternoon. Here's what you need to know. 
Via Benzinga
A patient’s story: Managing ulcerative colitis symptoms from diagnosis to treatment
(BPT) - Content sponsored and provided by Pfizer. Tiffany partnered with Pfizer to share her experience living with moderate to severe ulcerative colitis (UC). 
Via Brandpoint
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
Via Benzinga
Exposures COVID-19
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
Via Investor's Business Daily
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
One company's negative results can increase scrutiny of another's work. 
Via The Motley Fool
3 Blue-Chip Stocks to Buy on the Dip: June 2024
These top blue-chip stocks to buy on the dipare proven winners offering solid long-term growth, reliable dividends and excellent value. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
This is a matchup that the latecomer might not be able to win. 
Via The Motley Fool
5 Dividend Stocks Yielding at Least 5% to Buy Right Now for Passive Income
These companies pay well above average dividends. 
Via The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It in Favor of These 7 Top-Notch Stocks
More than a half-dozen of Wall Street's most-successful billionaire investors dumped shares of Nvidia during the March-ended quarter and made these seven stocks their top buys. 
Via The Motley Fool
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
These are the undervalued pharma stocks and represent companies with a deep research pipeline, that provides sustained growth visibility. 
Via InvestorPlace
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers. 
Via Benzinga
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. 
Via InvestorPlace
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. 
Via Investor's Business Daily
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
Price only tells you part of the story. 
Via The Motley Fool
7 Dividend Stocks to Buy Now: June 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
It doesn't take much to boost your passive income stream with these top dividend-paying stocks. 
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
You won't need much money to start investing in these great stocks. 
Via The Motley Fool
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns
These are the undervalued blue-chip stocks to buy, as they represent companies with strong fundamentals and robust cash flow outlooks. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.